Jason Rhodes Sells Shares of Dyne Therapeutics

Jason Rhodes, an insider at Dyne Therapeutics, Inc. (NasdaqGS: DYN), sold 95,900 shares of the company on June 24, 2026. The shares were sold at an average price of $21.02 each, bringing the total transaction value to approximately $2.02 million. This sale was part of a planned transaction.

Insider Buying and Selling at Dyne Therapeutics, Inc.

In addition to Jason Rhodes's recent sale, other insiders have also been active. On June 25, 2026, Rhodes sold another 24,100 shares at $21.10 each. Earlier, on June 23, 2026, he sold 147,760 shares at $21.13 per share. Dirk Kersten sold 73,286 shares at $21.05 on June 23, and 190,676 shares at $20.57 on June 22. Barry Greene, however, was buying, acquiring 57,463 shares on June 22.

Other Institutional Activity in Dyne Therapeutics

T. Rowe Price Investment Management, Inc. increased its holdings in Dyne Therapeutics by 13.2 million shares, ending with 30.8 million shares valued at about $558.1 million, a 75.5% increase. Janus Henderson Group PLC slightly reduced its stake by 240,346 shares, now holding 13.6 million shares worth $247.4 million, a 1.7% decrease. BlackRock, Inc. added 509,032 shares, bringing its total to 11.7 million shares valued at $212.1 million, a 4.5% increase. FMR LLC boosted its position by 2.3 million shares, holding 8.9 million shares worth $161.5 million, a 35.6% increase. Orbis Allan Gray Ltd grew its stake by 1.96 million shares to 6.8 million shares, valued at $122.6 million, a 40.8% increase.

Dyne Therapeutics, Inc. Stock Down 16.5%

Shares of Dyne Therapeutics, Inc. traded near $20.61 on Friday. The company has a market capitalization of approximately $3.41 billion. It operates in the biotechnology industry and is part of the healthcare sector. The stock's 52-week range is between $8.06 and $25.00, with a 50-day moving average of $18.39 and a 200-day moving average of $17.81. Dyne Therapeutics has a forward P/E ratio of -6.91 and a beta of 1.083. The company maintains a strong liquidity position with a current ratio of 19.92 and a quick ratio of 18.97.

Analysts Set New Price Targets

On May 15, 2026, Evercore ISI Group maintained a buy rating on Dyne Therapeutics with a price target of $33. Bernstein kept its hold rating with a $24 target on May 13, 2026. Earlier, Chardan Capital affirmed its buy rating with a $38 target on March 9, 2026. Morgan Stanley also maintained a buy rating, setting a target of $47 on March 3, 2026. Overall, the consensus among analysts is a strong buy, with a mean price target of $38.25 from 16 analyst opinions.

About Dyne Therapeutics

Dyne Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for neuromuscular diseases. Headquartered in Waltham, Massachusetts, the company is working on treatments for conditions like myotonic dystrophy type 1 and Duchenne muscular dystrophy. Led by CEO John G. Cox, Dyne Therapeutics employs 263 people and utilizes its FORCE platform to deliver disease-modifying therapeutics.

Bottom Line

Jason Rhodes's planned sale of shares in Dyne Therapeutics highlights ongoing insider activity at the company. Investors often track such transactions for potential insights into insider sentiment. Dyne Therapeutics remains a company to watch, with significant institutional interest and a strong buy rating from analysts. As always, remember that insider transactions are reported after the fact and may not reflect current positions.